Wantai Biological's (603392.SH) subsidiary passes Turkey GMP compliance inspection.

Zhitong Finance APP News, Wantai Biological (603392.SH) announced that recently, the production line of the nine-valent human papillomavirus vaccine (Escherichia coli) (referred to as the "nine-valent HPV vaccine") of its wholly-owned subsidiary Xiamen Wantai Canghai Biotechnology Co., Ltd. passed the GMP compliance inspection of the Turkish Medicines and Medical Devices Agency (referred to as "TITCK") and obtained the GMP certificate issued by TITCK. The acquisition of the GMP certificate issued by TITCK this time represents that the company's production and quality management system has passed the GMP compliance inspection of a PIC/S member country for the first time, which will have a positive impact on the overseas market expansion of the nine-valent HPV vaccine.